Low Income and Mortality in Young Adults Living With Type 2 Diabetes
Devin W. Steenkamp,Ashby F. Walker
DOI: https://doi.org/10.1001/jamanetworkopen.2024.43884
2024-11-13
JAMA Network Open
Abstract:The article titled "Income-Related Disparities in Mortality Among Young Adults With Type 2 Diabetes" 1 by Kim and colleagues reports on a retrospective cohort analysis of a very large cohort of more than 1.2 million individuals included in the South Korean National Health Insurance Service (NHIS) database. The authors describe important findings related to the association that low-income levels have with all-cause, cancer, and cardiovascular disease (CVD) mortality in individuals with type 2 diabetes (T2D), while aiming to delineate potential differences in health outcomes between young and older adults with T2D based on their socioeconomic status. 1 The major finding of this report was that low-income status was associated with a nearly 3-fold higher all-cause mortality in individuals living with T2D aged 20 to 39 years. In fact, among various examined factors, low income was the strongest factor associated with all-cause mortality in this age group. This contrasts with the 1.3-fold difference noted in individuals in the 60- to 79-year–old age group. The inverse association between income and mortality in diabetes is well described. 2 However, the income-related mortality disparity among young adults has not been previously described. This disparity was most pronounced for CVD mortality. It is unexpected that adults aged 20 to 40 years would have such a disproportionate relative increase in CVD mortality. Some of this increase may be driven by underutilization of medications—many of which reduce cardiovascular risk—and lower attendance at national preventive health examinations in this age group. Notably, routine clinic visit rates were similar across income groups, suggesting that even in a socialized nationwide medical system like South Korea's, where medical care is widely accessible, income remains an independent risk factor for mortality. Furthermore, even with a nationwide medical system, clinician implicit bias may affect treatment or result in barriers in utilization based on socioeconomic status (SES). Even within a system with freely available access to care, multiple factors may still influence utilization and outcomes. In 2023, Lancet released the Global Burden of Diabetes predictions that showed the alarming rates of increase in T2D prevalence globally, pointing to the fact that the rates of growth disproportionally impact historically marginalized and low-SES communities. 3 ,4 Given the growing population of young adults with diabetes in South Korea (and globally) and the increasing prevalence and disparities related to diabetes complications across the world, 5 ,6 this report further supports the growing emphasis on health care policies aimed to reduce health disparities in adults with T2D 7 —but now with an additional call to consider younger adults in these policy decisions. Findings presented in this report also demonstrate the importance of understanding the complex interplay or intersectionality of various status characteristics, such as age and SES. A major strength of this manuscript is the very large cohort size with universal claims data linked with income data for every South Korean citizen. A major limitation to consider is that the median follow-up duration was only 9.4 years, a relatively short duration for long-term mortality outcomes, especially for young adults. Given significant differences in medication utilization for young adults with T2D in this cohort from South Korea, more research is needed to understand related barriers and facilitators that exist within a single-payer universal health care system like the NHIS. Future research focused on the promotion of health equity for young adults with T2D in South Korea should include multilayered interventions that incorporate recommendations from Lancet 's Global Burden of Diabetes series to change the ecosystem, build community capacity, and improve the clinical practice environment. 3 ,7 Published: November 12, 2024. doi:10.1001/jamanetworkopen.2024.43884 Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2024 Steenkamp DW et al. JAMA Network Open . Corresponding Author: Devin W. Steenkamp, MD, Boston University–Medical Campus, 72 E. Concord St, Boston, MA 02118 (desteenk@bu.edu). Conflict of Interest Disclosures: Dr Steenkamp reported receiving grants from Abbott Diabetes Care, MannKind, Tandem Diabetes Care, and Novo Nordisk outside the submitted work. No other disclosures were reported.
medicine, general & internal